Dihexa vs VIP (Vasoactive Intestinal Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dihexa
Dihexa is a nootropic peptide derived from angiotensin IV. It has shown remarkable cognitive-enhancing properties in animal studies, being described as potentially millions of times more potent than BDNF.
Full details →VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →Side-by-Side Comparison
| Aspect | Dihexa | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Mechanism | Acts as a hepatocyte growth factor (HGF) potentiator by binding to its receptor c-Met. Promotes synaptogenesis, neuronal survival, and cognitive enhancement through this pathway. | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. |
| Typical Dosage | Research dosing is highly variable due to extreme potency. Typical range: 10-40mg orally or sublingually. Start with lowest doses due to potency. | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. |
| Administration | Can be taken orally, sublingually, or intranasally. Extremely potent - careful dosing is essential. Best used cyclically. | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. |
| Side Effects | Limited human data. Reported effects include headache, temporary brain fog during adjustment, and potential mood changes. | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. |
| Best For |